Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcus Biosciences Inc
(NY:
RCUS
)
15.73
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Nov 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Arcus Biosciences Inc
< Previous
1
2
3
4
5
Next >
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
November 06, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
November 05, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
October 30, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
October 24, 2024
From
Arcus Biosciences
Via
Business Wire
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
October 24, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
October 22, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
October 09, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
October 09, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
October 02, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
September 24, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
September 10, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
August 27, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
August 26, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
August 21, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update
August 08, 2024
From
Arcus Biosciences
Via
Business Wire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
August 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update
July 25, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
July 09, 2024
From
Arcus Biosciences
Via
Business Wire
Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia
July 08, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
June 25, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
June 11, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
June 10, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 06, 2024
From
Arcus Biosciences
Via
Business Wire
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
June 02, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
June 01, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
May 24, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
May 09, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
May 08, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
May 02, 2024
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
April 24, 2024
From
Arcus Biosciences
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.